Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma

Completed · Phase 2

Conditions studied: Marginal Zone Lymphoma, B-cell Lymphoma

In brief

Phase 2, open-label, non-randomized, monotherapy study to evaluate the safety and efficacy of ibrutinib in subject with relapsed/refractory Marginal Zone Lymphoma (MZL).

Key facts

Study ID

NCT01980628

Run by

Pharmacyclics LLC.

People needed

63

Starts

2013-12-01

Expected to finish

2017-10-02

Last updated by the study team

2019-10-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Site Reference ID/Investigator# 837 — Tucson, Arizona, United States
• Site Reference ID/Investigator# 047 — Duarte, California, United States
• Site Reference ID/Investigator# 377 — Santa Monica, California, United States
• Site Reference ID/Investigator# 763 — West Palm Beach, Florida, United States
• Site Reference ID/Investigator# 033 — Atlanta, Georgia, United States
• Site Reference ID/Investigator# 370 — Chicago, Illinois, United States
• Site Reference ID/Investigator# 195 — Detroit, Michigan, United States
• Site Reference ID/Investigator# 350 — New Hyde Park, New York, United States
• Site Reference ID/Investigator# 745 — New York, New York, United States
• Site Reference ID/Investigator # 200 — New York, New York, United States
• Site Reference ID/Investigator # 407 — New York, New York, United States
• Site Reference ID/Investigator# 220 — Hershey, Pennsylvania, United States
• Site Reference ID/Investigator# 348 — Seattle, Washington, United States
• Site Reference ID/Investigator# 560 — Ghent, Oost-vlaanderen, Belgium
• Site Reference ID/Investigator# 142 — Pierre-Bénite, Auvergne-Rhône-Alpes, France
• Site Reference ID/Investigator# 737 — Rouen, Haute-normandie, France
• Site Reference ID/Investigator# 750 — Lille, Hauts-de-France, France
• Site Reference ID/Investigator# 749 — La Roche-sur-Yon, Pays de la Loire Region, France
• Site Reference ID/Investigator# 736 — Nantes, Pays de la Loire Region, France
• Site Reference ID/Investigator# 742 — Rennes, France
• Site Reference ID/Investigator# 735 — Paris, Île-de-France Region, France
• Site Reference ID/Investigator# 669 — Mainz, Rhineland-Palatinate, Germany
• Site Reference ID/Investigator# 030 — Manchester, England, United Kingdom
• Site Reference ID/Investigator# 814 — Oxford, England, United Kingdom
• Site Reference ID/Investigator# 368 — Plymouth, England, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.